Page 34 of 35

BMJ Open

3 4

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	1, 2
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration			
	<u>#2</u>	If registered, provide the name of the registry (such as PROSPERO) and registration number	7
Authors			
Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the guarantor of the review	16
	For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 35 of 35 BMJ Open

1 2	Amendments			
3 4 5 6 7		<u>#4</u>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	7
8 9 10	Support			
11 12 13 14	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	16
	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	N/A
15 16	Role of sponsor or	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any,	N/A
17 18	funder		in developing the protocol	
19 20	Introduction			
21 22 23 24	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is already known	4-6
25 26 27 28 29 30	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	7
31 32	Methods			
33 34 35 36 37 38 39 40 41 42 43 44	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	7-10
	Information sources	<u>#9</u>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8-9
45 46 47 48	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	20-21
49 50 51 52 53 54 55 56 57 58	Study records - data management	<u>#11a</u>	Describe the mechanism(s) that will be used to manage records and data throughout the review	9
	Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

59

60

Page 36 of 35

10

BMJ Open 1 Study records - data #11c Describe planned method of extracting data from reports (such as 2 collection process 3 4 5 6 Data items #12 7 8 9 and simplifications 10 11 Outcomes and #13 12 13 prioritization 14 rationale 15 16 17 Risk of bias in #14 18 individual studies 19 20 21 synthesis 22 23 Data synthesis #15a 24 25 synthesised 26 27 Data synthesis 28 29 30 31 32 33 34 Data synthesis 35 36 37 38 Data synthesis 39 summary planned 40 41 42 Meta-bias(es) #16 43 44 45 Confidence in #17 46 47 cumulative (such as GRADE) 48 49 evidence 50 51 52 53 54 55 56 57 58

piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators List and define all variables for which data will be sought (such as 10-11 PICO items, funding sources), any pre-planned data assumptions 8 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data Describe criteria under which study data will be quantitatively 12-13 #15b If data are appropriate for quantitative synthesis, describe planned 12-13 summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall's τ) #15c Describe any proposed additional analyses (such as sensitivity or 13 subgroup analyses, meta-regression) #15d If quantitative synthesis is not appropriate, describe the type of 13 Specify any planned assessment of meta-bias(es) (such as 11 publication bias across studies, selective reporting within studies) Describe how the strength of the body of evidence will be assessed 11

None The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using https://www.goodreports.org/, a tool made by the <u>EQUATOR Network</u> in collaboration with <u>Penelope.ai</u>

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml